Nektar Press Release
Nektar Therapeutics Results for Q2 of 2019
Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2019.
Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December . . .
This content is for paid subscribers.
Impacting News August 9, 2019